BioSpace News Archive

The multi-center study met its primary endpoint with 53% of CIS ± Ta/T1 patients achieving a complete response (CR) at three months, and 24% continuing to show a CR at 12 months

NGM Biopharmaceuticals, Inc. announced the expansion of its Board of Directors with the appointment of Shelly Guyer, who currently serves as Chief Financial Officer of Invitae Corporation.

New research finds that while patients are interested in using digital healthcare services, they still value high-quality interactions with their doctors.

Hensler Surgical Products, LLC, dba Hensler Surgical Technologies filed a federal lawsuit in the United States District Court for the Southern District of North Carolina accusing competitor Tobra Medical, Inc. of infringing newly-issued U.S. Patent No. 10,493,183.

Enzyre, which is developing breakthrough ambulant diagnostic technology for coagulation testing, today announced that it has entered into a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop a diagnostic device that will enable hemophilia patients to determine their coagulation status at home.

Select Medical Holdings Corporation, announced that Select Medical Corporation has priced its private placement of $675 million aggregate principal amount of its 6.250% senior notes due 2026 as additional notes under the indenture pursuant to which it previously issued $550 million of 6.250% senior notes due 2026.

This is the first peer-reviewed publication of positive results from a pivotal study evaluating an investigational therapy for NASH.

VISTASEAL™, a fibrin sealant developed by Grifols for biosurgical bleeding-control, is marketed and distributed by Ethicon and is the result of the two companies’ strategic collaboration

Eight iconic buildings in New York City, including the world-renowned Empire State Building, will light up blue on Wednesday, December 11 to commemorate the 36th annual Empire Ball and to shine a spotlight on the need for a diabetes cure.

Canada’s leading generic drug manufacturer, Apotex, announced today that its first shipment of the drug tamoxifen has been released to the Canadian market